<DOC>
	<DOCNO>NCT00978263</DOCNO>
	<brief_summary>The investigator design prospective , randomize control study compare efficacy safety basal insulin glargine therapy metformin-based OADs correction glucose toxicity short period intensive insulin therapy .</brief_summary>
	<brief_title>Comparison Glargine Oral Antidiabetic Drugs ( OADs ) Newly Diagnosed Type 2 Diabetes</brief_title>
	<detailed_description>Detailed Description : OBJECTIVE—Type 2 diabetes associate defect insulin secretion insulin sensitivity . Hyperglycemia may aggravate defect , feature know glucose toxicity . Previous study show acute correction hyperglycemia subject long-standing type 2 diabetes give short-term improvement glycemic control discontinuation insulin . The current study attempt identify whether basal insulin glargine metformin-based OADs management would long-term benefit newly diagnose type 2 diabetes short-term intensive insulin therapy . RESEARCH DESIGN AND METHODS—Newly diagnose type 2 diabetic patient ( fast blood glucose &gt; 200 mg/dL random blood glucose &gt; 300 mg/dL ) hospitalize treated intensive insulin injection 10 14 day . HbA1c measure intensive insulin injection . After discharge , patient randomize receive basal insulin injection metformin-based OADs management . Patients follow clinic adjust medication accord blood glucose level . HbA1c measure 6 month later.After six-month intervention , patient continually follow another six month . Subjects receive oral glucose tolerance test ( OGTT ) intensive insulin therapy end 6th 12th month . EXPECTED RESULTS—We expect basal insulin glargine , compare metformin-based OAD treatment , could effectively maintain adequate glycemic control newly diagnose type 2 diabetes short-term intensive insulin therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Newly diagnose type 2 diabetic patient . 2 . Drug naïve , severe hyperglycemia ( fast plasma glucose &gt; 11.1mmol/L random plasma glucose &gt; 16.7mmol/L ) 3 . Those age 30 70 year old inject insulin . 1 . Established type 1 diabetes positive antiglutamic acid decarboxylase antibody ; 2 . Malignancy , pregnancy lactating ; 3 . History ketoacidosis ; 4 . Hepatic dysfunction alanine aminotransferase 2.5 time high upper limit normal ; serum creatinine &gt; 2 mg/dl ; 5 . Poor blood pressure control ( SBP &gt; 180mmHg DBP &gt; 110mmHg ) ; 6 . Definite coronary artery disease , heart failure , leave ventricular hypertrophy ; 7 . Severe anemia ; acute severe chronic diabetes complication ; 8 . BMI &lt; 18 kg/m2 ≥41kg/m2 ; 9 . History alcohol abuse drug abuse ; 10 . Mental disorder endocrine disorder ; dysfunction digestion absorption ; 11 . Chronic disease need longterm glucocorticoid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>